Maze Therapeutics [MAZE] vs Recursion [RXRX] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Maze Therapeutics Inc. wins in 7 metrics, Recursion Pharmaceuticals Inc. wins in 7 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Maze Therapeutics Inc. | Recursion Pharmaceuticals Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 189.50 | -2.44 | Maze Therapeutics Inc. |
| Price-to-Book Ratio | 3.68 | 1.64 | Recursion Pharmaceuticals Inc. |
| Debt-to-Equity Ratio | 6.57 | 6.89 | Maze Therapeutics Inc. |
| PEG Ratio | -5.25 | 0.04 | Recursion Pharmaceuticals Inc. |
| EV/EBITDA | -7.11 | -2.10 | Recursion Pharmaceuticals Inc. |
| Profit Margin (TTM) | 0.00% | 4.45% | Recursion Pharmaceuticals Inc. |
| Operating Margin (TTM) | 0.00% | -328.80% | Maze Therapeutics Inc. |
| Return on Equity | -47.52% | -59.54% | Maze Therapeutics Inc. |
| Return on Assets (TTM) | -28.01% | -27.72% | Recursion Pharmaceuticals Inc. |
| Free Cash Flow (TTM) | $-112.73M | $-380.44M | Maze Therapeutics Inc. |
| 1-Year Return | 164.34% | -14.11% | Maze Therapeutics Inc. |
| Price-to-Sales Ratio (TTM) | N/A | 24.83 | N/A |
| Enterprise Value | $998.67M | $1.19B | Recursion Pharmaceuticals Inc. |
| EV/Revenue Ratio | N/A | 15.88 | N/A |
| Gross Profit Margin (TTM) | N/A | 59.62% | N/A |
| Revenue per Share (TTM) | N/A | $0 | N/A |
| Earnings per Share (Diluted) | $-3.05 | $-1.44 | Recursion Pharmaceuticals Inc. |
| Beta (Stock Volatility) | N/A | 1.01 | N/A |
| Short % of Float | 9.32% | 34.94% | Maze Therapeutics Inc. |
Maze Therapeutics Inc. vs Recursion Pharmaceuticals Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Maze Therapeutics Inc. | 2.35% | -4.57% | -7.69% | -43.73% | -40.08% | -37.49% |
| Recursion Pharmaceuticals Inc. | -3.88% | 9.46% | -1.42% | -1.98% | -25.54% | -17.38% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Maze Therapeutics Inc. | 164.34% | 65.89% | 65.89% | 65.89% | 65.89% | 65.89% |
| Recursion Pharmaceuticals Inc. | -14.11% | -56.38% | -87.80% | -88.53% | -88.53% | -88.53% |
Performance & Financial Health Analysis: Maze Therapeutics Inc. vs Recursion Pharmaceuticals Inc.
| Metric | MAZE | RXRX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.29B | $1.85B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,174,955 | 11,402,630 |
| 90 Day Avg. Volume | 1,253,272 | 12,390,473 |
| Last Close | $24.86 | $3.47 |
| 52 Week Range | $9.83 - $53.65 | $2.77 - $7.18 |
| % from 52W High | -53.66% | -51.67% |
| All-Time High | $53.65 (Mar 16, 2026) | $42.81 (Jul 12, 2021) |
| % from All-Time High | -53.66% | -91.89% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 6.82% |
| Quarterly Earnings Growth | N/A | 6.84% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.04% |
| Operating Margin (TTM) | 0.00% | -3.29% |
| Return on Equity (TTM) | -0.48% | -0.60% |
| Debt to Equity (MRQ) | 6.57 | 6.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.20 | $2.14 |
| Cash per Share (MRQ) | $6.88 | $1.41 |
| Operating Cash Flow (TTM) | $-111,940,000 | $-371,808,000 |
| Levered Free Cash Flow (TTM) | $-72,523,872 | $-208,521,744 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Maze Therapeutics Inc. vs Recursion Pharmaceuticals Inc.
| Metric | MAZE (Apr 24, 2026) | RXRX (Apr 26, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 189.50 | -2.44 |
| Forward P/E | -7.61 | -4.12 |
| PEG Ratio | -5.25 | 0.04 |
| Price to Sales (TTM) | N/A | 24.83 |
| Price to Book (MRQ) | 3.68 | 1.64 |
| Market Capitalization | ||
| Market Capitalization | $1.29B | $1.85B |
| Enterprise Value | $998.67M | $1.19B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 15.88 |
| Enterprise to EBITDA | -7.11 | -2.10 |
| Risk & Other Metrics | ||
| Beta | N/A | 1.01 |
| Book Value per Share (MRQ) | $7.20 | $2.14 |
Financial Statements Comparison: Maze Therapeutics Inc. vs Recursion Pharmaceuticals Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | MAZE (2025) | RXRX (2025) |
|---|---|---|
| Revenue/Sales | 0 | 74.26M |
| Cost of Goods Sold | N/A | 70.95M |
| COGS % of Revenue | - | 95.6% |
| Gross Profit | N/A | 3.30M |
| Gross Margin | - | 4.4% |
| Research & Development | 108.45M | 475.27M |
| Operating Income (EBIT) | -142.90M | -648.13M |
| Operating Margin | - | -872.8% |
| EBITDA | -140.50M | -559.38M |
| EBITDA Margin | - | -753.3% |
| Pre-Tax Income | -131.12M | -644.90M |
| Pre-Tax Income % of Revenue | - | -868.5% |
| Income Tax | 0 | -136,000 |
| Income Tax % of Revenue | - | -0.2% |
| Net Income (Profit) | -131.12M | -644.76M |
| Profit Margin | - | -868.3% |
Balance Sheet & Liquidity Metrics
| Metric | MAZE (2025) | RXRX (2025) |
|---|---|---|
| Cash & Equivalents | 189.25M | 743.29M |
| Total Current Assets | 349.72M | 812.85M |
| Total Current Assets % of Revenue | - | 1,094.7% |
| Total Current Liabilities | 22.56M | 147.71M |
| Total Current Liabilities % of Revenue | - | 198.9% |
| Long-Term Debt | 18.51M | 56.21M |
| Long-Term Debt % of Revenue | - | 75.7% |
| Total Shareholders Equity | 354.97M | 1.13B |
| Retained Earnings | -489.55M | -2.08B |
| Retained Earnings % of Revenue | - | -2,795.7% |
| Property, Plant & Equipment | 36.07M | 158.71M |
Cash Flow Statement Comparison
| Metric | MAZE (2025) | RXRX (2025) |
|---|---|---|
| Operating Cash Flow | -112.48M | -422.39M |
| Operating Cash Flow % of Revenue | - | -568.8% |
| Capital Expenditures | -794,000 | -6.47M |
| Free Cash Flow | -112.73M | -380.44M |
| FCF Margin | - | -512.3% |
| Debt Repayment | N/A | -8.43M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MAZE | RXRX |
|---|---|---|
| Shares Short | 3.89M | 174.40M |
| Short Ratio | 3.35 | 14.00 |
| Short % of Float | 9.32% | 34.94% |
| Shares Outstanding | 49.34M | 528.18M |
| Float Shares | 27.70M | 510.29M |
| % Held by Insiders | 1.65% | 2.85% |
| % Held by Institutions | 93.39% | 64.60% |
| % Held by Public | 4.96% | 32.55% |
Dividend Analysis & Yield Comparison: Maze Therapeutics Inc. vs Recursion Pharmaceuticals Inc.
| Metric | MAZE | RXRX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |